Adheris Health Limited · ASX:AHE
Adheris Health — FY2024 Earnings Presentation
34 slides from Adheris Health's earnings presentation, Aug 29, 2024
Slide 1: One Company, One Platform, One Purpose.
FY24 Full-Year Results | ASX:MDR One Company, One Platform, One Purpose. 29 August 2024
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation provides general information about completeness of the information or for any of the opinions regulatory requirements. This presentation does not constitute MedAdvisor Solutions which is current at the date this contained herein or for any errors, om
Slide 3: Agenda
Agenda 1 FY24 highlights 2 One company 3 One platform 4 One purpose Rick Ratliff Ancila Desai CEO & Managing Director Global Chief Financial Officer 5 Continuing our success in FY25 & Company Secretary 6 Q&A 3 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 4: We have realised our Pathway to Profitability
We have realised our Pathway to Profitability, “ establishing a foundation for future growth by initiating strategic investments in technology development, Shared Services, and scalable patient engagement solutions. ” Rick Ratliff CEO & Managing Director 4 FY24 Investor Presentation: One Company, On
Slide 5: FY24 highlights
FY24 highlights 5 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 6: Key highlights
Key highlights MedAdvisor Solutions delivers inaugural profit with $122.1M record full-year revenue, up by 24.6%. Strong momentum across key markets, with Promising outlook for FY25, with anticipated continued growth in both the US and Australia continued growth driven by the increasing adoption of
Slide 7: Delivering on our commitment: initial profitability
Delivering on our commitment: initial profitability In FY24, we realised our Pathway to Profitability, a key milestone in our 5-year plan. Global platform Business operations Product innovation Evolution to one platform lowers Strategic changes create Innovation improves the user operating expenses
Slide 8: One company
One company 8 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 9: MedAdvisor Solutions: group highlights
MedAdvisor Solutions: group highlights In FY24, we delivered on our Pathway to Profitability with inaugural EBITDA and NPAT profitablity. Revenue Gross margin $122.1M up by 24.6% YoY $74.2M up by 24.9% YoY EBITDA Strong cash position $7.0M increase of $10.1M YoY $15.6M All financials are in AUD, unl
Slide 10: Record revenue
Record revenue $122.1M Revenue reflected robust growth YoY. Group operating revenue $98.4M MedAdvisor Solutions delivered milestone MDR US MDR ANZ $98.0M financial results in FY24, with group-level revenue of $122.1 million, representing a 24.6% $78.1M increase over FY23, supported by record perform
Slide 11: Gross profit gains
$23.7 Gross profit gains Gross profit rose significantly YoY. $74.2M Gross profit rose by 24.9% to $74.2 million and gross margin improved to 60.8%, driven by globalised operations, diversified $59.4M brand & vaccine revenues, realigned pharmacy fees, and higher-margin, THRiV- powered patient engage
Slide 12: Inaugural EBITDA profitability
Inaugural EBITDA profitability EBITDA improvement $14.8M drove profitability in FY24. ($0.2M) Revenue and margin uplift: Expanding pharma ($1.7M) ($0.4M) relationships, instituting new fee structures, growing patient engagement programs powered by THRiV. ($1.1M) $9.6M Marketing & communications: To
Slide 13: Strong cash position, creating opportunities to fund investments for growth
Strong cash position, creating opportunities to fund investments for growth $120.4M Reported cash flow = strong cash position. Receipts from customers and payments to suppliers: Strong customer receipt growth from both the US and AU, and disciplined working capital management (including tax payments
Slide 14: A culture of collaboration
A culture of collaboration In FY24, we focused on alignment as “One MedAdvisor” with an emphasis on collaboration—channeling collective strengths and knowledge to drive positive patient impact and deliver on business objectives. Unfavourable: 5% FY24 engagement survey (favourable scores) Neutral: 12
Slide 15: FY24 highlights—ANZ
FY24 highlights—ANZ In ANZ, we achieved strong YoY growth as our pharmacy network and services expanded. Revenue $23.7M up by 19.1% YoY Hi Paul, your appointment is next Tuesday at 10am Gross profit Average script uplift from AU adherence programs $20.7M up from $16.7M FY23 ~41% 82% Gross margin 87.
Slide 16: Case study: Scope of Practice programs & pilot
Case study: Scope of Practice programs & pilot Expanded Scope of Practice (ESoP): Putting community pharmacies at the centre of general practice across Australia. Scope of Practice programs and pilots were In FY24, we built the software to launch designed to address regional demand for the N. Queens
Slide 17: FY24 highlights—US
FY24 highlights—US In the US, we achieved strong YoY growth with our continued shift to omnichannel solutions aligned with pharma strategies. 7.6x Revenue Growth driven by $98.4M up by 26% YoY 20+ new brands and omnichannel engagement YoY omnichannel Gross profit platform revenue $53.5M 45% 36% up f
Slide 18: FY24 program growth
FY24 program growth Our pharma-sponsored Therapeutic categories for pharma-sponsored programs in the US (non-vaccine) programs continued to Neurologic: 1% Thyroid: 1% Inflammation: 1% Other: 1% deliver value to patients. Gastrointestinal: 5% HIV: 5% Cardiovascular: 37% Patient engagement programs po
Slide 19: Case study: vaccine growth
Case study: vaccine growth MedAdvisor Solutions’ Results THRiV patient platform realises significant growth from vaccines. +31% YoY growth The COVID-19 pandemic reignited vaccine innovation, strengthening the business case for vaccines. 2.5X–5.1X average ROI By doubling our vaccine program 89.8M man
Slide 20: UK Update—Charac
UK Update—Charac In FY24, we completed the initial $1M minority investment in Charac and successfully migrated MedAdvisor’s contracted pharmacies to Charac. We expect to launch a Charac eCommerce solution in Australia in 2Q FY25. 2,300+ • Launching eCommerce and home delivery solution in ANZ Contrac
Slide 21: One platform
One platform 21 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 22: The evolution of our platform
The evolution of our platform In FY24, we took steps to Awareness improve our platform, setting the foundation for deeper engagement & broader scale. Care Commerce The evolving global, intelligent THRiV platform will serve as a universal solution, regionally scalable, offering diverse services and c
Slide 23: AI & MedAdvisor: a strategic roadmap
AI & MedAdvisor: a strategic roadmap “By enabling stronger Responsible AI: guiding principles Targeted use cases omnichannel patient Privacy Patient engagement engagement, powered by Safety Patient App our platform, THRiV, AI will be an Security MedAdvisor for Pharmacy essential tool in empowering t
Slide 24: Sustaining growth with Transformation 360º
Sustaining growth with Transformation 360º TRANSFORMATION In FY25, we will launch Transformation 360°, investing in the evolution of future patient engagement and strengthening our foundation for sustainable, profitable growth, prioritising: US platform transformation MedAdvisor App Empowering great
Slide 25: One purpose
One purpose 25 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 26: Roadmap to the future
Roadmap to the future As we continue the rollout The pharmacy of our 5-year strategy, of the future: our emphasis in FY25 is the Personalisation and enhanced patient pursuit of innovative patient engagement engagement solutions— for pharma and pharmacy partners, and beyond … • AI-enabled platform tr
Slide 27: 5-year strategic plan: identified opportunities
5-year strategic plan: identified opportunities 4 key areas with significant Total Addressable Market of >$20B that MedAdvisor has the capability to grow into and expand, furthering our essential goal: patient engagement. Pharmacy services Driving growth Omnichannel patient engagement • Expanded Sco
Slide 28: 5-year strategic plan: financial targets
5-year strategic plan: financial targets Targeting strong organic and inorganic growth, margin expansion, and the diversification of revenue streams. 5-year strategic plan: Targeted revenue diversification: ~$250M >20% EBITDA 20-25% revenue CAGR margins Australia United States Foundation Pharmacy se
Slide 29: Continuing our success in FY25
Continuing our success in FY25 29 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 30: Momentum into FY25
Momentum into FY25 The significant advancements achieved in FY24 provide a strong foundation for continued growth into FY25. We anticipate this growth to be driven by the increasing adoption of our omnichannel patient engagement solutions and the introduction of new, innovative service offerings. 30
Slide 31: Momentum into FY25
Momentum into FY25 Continued pharmacy network development We continue to strengthen relationships and deliver new & improved services to our pharmacy partners. AI opportunities We will introduce new AI capabilities to power the user experience and enhance the value of our products for pharmacists &
Slide 32: Q&A
Q&A 32 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 33: Appendix
Appendix 33 FY24 Investor Presentation: One Company, One Platform, One Purpose.
Slide 34: Our social responsibility journey
Our social responsibility journey In FY24, we continued to develop an Diversity and inclusion 4% 1% appropriate strategy to identify and 18–24 yrs manage ESG risks, undertaking a 17% 30% 25–34 yrs 35–44 yrs materiality assessment, and compiling a Age of 40% Employees 60% 44% Board 56% 45–54 yrs empl